Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial
1
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background/Aims: To evaluate the efficacy and safety of a controlled release, once-daily formulation of mosapride (UI05MSP015CT) in patients with functional dyspepsia (FD). Methods: Patients with FD were randomly assigned (1:1) to receive either UI05MSP015CT (15 mg once a day, study group) or mosapride (5 mg three times a day, control group) and corresponding placebo for 4 weeks. The primary endpoint was a change in the gastrointestinal symptom score (GIS) evaluated at enrollment and after 4 weeks. Secondary endpoints were changes in the Nepean Dyspepsia Index-Korean version (NDI-K), rate of satisfactory symptom relief, and rate of adverse events. Results: A total of 138 patients were enrolled (female, 73.9%; mean age, 44.0±15.4 years). After excluding patients who violated the study protocol, 59 and 58 patients from the study and control groups, respectively, were included in the per-protocol analysis. No difference was observed in drug compliance between the control and study groups (97.07%±4.52% vs 96.85%±6.05%, p=0.870). Changes in GIS scores were –9.69±6.44 and –10.01±5.92 in the study and control groups. The mean difference in GIS change between groups was 0.33 (95% confidence interval, –1.75 to 2.41), demonstrating non-inferiority of UI- 05MSP015CT (p=0.755). The rate of satisfactory symptom relief was not different between the study and control groups (39.0% vs 56.9%, p=0.053). No differences in change in NDI-K score (14.3 vs 16.9, p=0.263) or rates of adverse events (12.9% vs. 4.4%, p=0.062) were observed between the study and control groups. Conclusions: Once-daily mosapride is not inferior to conventional mosapride in efficacy and is safe in patients with FD.
Abstract
Background/Aims: To evaluate the efficacy and safety of a controlled release, once-daily formulation of mosapride (UI05MSP015CT) in patients with functional dyspepsia (FD). Methods: Patients with FD were randomly assigned (1:1) to receive either UI05MSP015CT (15 mg once a day, study group) or mosapride (5 mg three times a day, control group) and corresponding placebo for 4 weeks. The primary endpoint was a change in the gastrointestinal symptom score (GIS) evaluated at enrollment and after 4 weeks. Secondary endpoints were changes in the Nepean Dyspepsia Index-Korean version (NDI-K), rate of satisfactory symptom relief, and rate of adverse events. Results: A total of 138 patients were enrolled (female, 73.9%; mean age, 44.0±15.4 years). After excluding patients who violated the study protocol, 59 and 58 patients from the study and control groups, respectively, were included in the per-protocol analysis. No difference was observed in drug compliance between the control and study groups (97.07%±4.52% vs 96.85%±6.05%, p=0.870). Changes in GIS scores were –9.69±6.44 and –10.01±5.92 in the study and control groups. The mean difference in GIS change between groups was 0.33 (95% confidence interval, –1.75 to 2.41), demonstrating non-inferiority of UI- 05MSP015CT (p=0.755). The rate of satisfactory symptom relief was not different between the study and control groups (39.0% vs 56.9%, p=0.053). No differences in change in NDI-K score (14.3 vs 16.9, p=0.263) or rates of adverse events (12.9% vs. 4.4%, p=0.062) were observed between the study and control groups. Conclusions: Once-daily mosapride is not inferior to conventional mosapride in efficacy and is safe in patients with FD.
참고문헌 (23)
- Pan H, "5-HT1A and 5-HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons", Am J Physiol, 266(2), pp.G230~G238 (1994)
- Tonini M, "Effects of cisapride on cholinergic neurotransmission and propulsive motility in the guinea pig ileum", Gastroenterology, 96(5), pp.1257~1264 (1989)[DOI]
- Curran MP, "Mosapride in gastrointestinal disorders", Drugs, 68, pp.981~991 (2008)[DOI]
- Hongo M, "Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS)", J Gastroenterol Hepatol, 27, pp.62~68 (2012)[DOI]
- Kinoshita Y, "Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia", Aliment Pharmacol Ther, 21(Suppl 2), pp.37~41 (2005)[DOI]
- Otaka M, "New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline", Aliment Pharmacol Ther, 21(Suppl 2), pp.42~46 (2005)[DOI]
- 조유경, "기능성 소화불량증의 삶의 질에 대한 모사프리드의 효과", 대한소화기학회지, 43(3), pp.160~167 (2004), 대한소화기학회
- A phase 1, randomized, open-label, single dose, 3-treatment, 3-period Williams-design to assess the pharmacokinetic characteristics and food effect of mosapride citrate controlled-release tablets compared with mosapride citrate immediate-release tablets in healthy male subjects: clinical trial report, "Hong J", Korea United Pharm, 1~48 (2013)
- Drossman DA, "The functional gastrointestinal disorders and the Rome III process", Gastroenterology, 130, pp.1377~1390 (2006)[DOI]
- Rosch W, "A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia", Z Gastroenterol, 40, pp.401~408 (2002)[DOI]
- Madisch A, "Treatment of functional dyspepsia with a herbal preparation: a doubleblind, randomized, placebo-controlled, multicenter trial", Digestion, 69, pp.45~52 (2004)[DOI]
- Camilleri M, "Current management strategies and emerging treatments for functional dyspepsia", Nat Rev Gastroenterol Hepatol, 10, pp.187~194 (2013)[DOI]
- 박종규, "기능성 소화불량증의 최근 동향", 대한소화기학회지, 64(3), pp.133~141 (2014), 대한소화기학회
- 박재명, "Functional Gastrointestinal Disorders Diagnosed by Rome III Questionnaire in Korea", Journal of Neurogastroenterology and Motility (JNM), 17(3), pp.279~286 (2011), 대한소화기 기능성질환∙운동학회
- Madisch A, "A plant extract and its modified preparation in functional dyspepsia: results of a double-blind placebo controlled comparative study", Z Gastroenterol, 39, pp.511~517 (2001)[DOI]
- Matsueda K, "A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia", Gut, 61, pp.821~828 (2012)[DOI]
- Paes AH, "Impact of dosage frequency on patient compliance", Diabetes Care, 20, pp.1512~1517 (1997)[DOI]
- 최창환, "Second Korean guidelines for the management of ulcerative colitis", Intestinal research, 15(1), pp.7~37 (2017), 대한장연구학회
- Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence consensus report, 2012, pp.61, 646~664
- Hiroto Miwa, "Asian Consensus Report on Functional Dyspepsia", Journal of Neurogastroenterology and Motility (JNM), 18(2), pp.150~168 (2012), 대한소화기 기능성질환∙운동학회[DOI]
- Du LJ, "Helicobacter pylori eradication therapy for functional dyspepsia: systematic review and meta-analysis", World J Gastroenterol, 22, pp.3486~3495 (2016)[DOI]
- Hanley MJ, "Effect of obesity on the pharmacokinetics of drugs in humans", Clin Pharmacokinet, 49, pp.71~87 (2010)[DOI]
- Talley NJ, "Functional dyspepsia", N Engl J Med, 373, pp.1853~1863 (2015)[DOI]